Table 2 Implantable Cardioverter Defibrillation Subject Characteristics
From: Onset of the COVID-19 pandemic reduced active time in patients with implanted cardiac devices
|  | < 2h active time (N = 130) | ≥ 2h active time (N = 114) | P-Value |
|---|---|---|---|
Age | 72 ± 12 | 62 ± 14 | < 0.0001 |
Sex (% Women) | 35.4 | 21.9 | 0.02 |
Number of Leads | Â | Â | 0.02 |
Single | 23.1 | 38.6 | - |
Dual | 30.8 | 28.1 | - |
Biventricular | 46.2 | 33.3 | - |
Comorbidities | |||
Hypertension (%) | 80.8 | 66.7 | 0.01 |
Dyslipidemia (%) | 73.1 | 62.3 | 0.07 |
Ischemic Heart Disease (%) | 74.6 | 56.1 | 0.002 |
Mitral Regurgitation (% moderate or greater) | 12.0 | 9.2 | 0.75 |
History of Atrial Fibrillation (%) | 53.8 | 45.6 | 0.20 |
LBBB (%) | 40.0 | 34.2 | 0.35 |
LVEF < 35% (%) | 41.5 | 23.7 | 0.003 |
Diabetes (%) | 18.9 | 19.3 | 0.01 |
Creatinine Clearance < 60 mL/min (%) | 43.8 | 14.9 | < 0.001 |
Smoking (% current) | 14.6 | 7.9 | 0.10 |
Medications | |||
Aspirin (%) | 60.0 | 63.2 | 0.61 |
Beta Blockers (%) | 94.6 | 95.6 | 0.72 |
Calcium Channel Blockers (%) | 10.0 | 22.8 | 0.006 |
ACE Inhibitors (%) | 28.5 | 35.1 | 0.27 |
Angiotensin II Receptor Blockers (%) | 17.7 | 21.9 | 0.41 |
Angiotensin Receptor/Neprolysin Inhibitor (%) | 24.6 | 14.0 | 0.04 |
Nitrates (%) | 23.8 | 15.8 | 0.12 |
HMG-CoA Reductase Inhibitor (%) | 75.4 | 63.2 | 0.04 |
Amiodarone (%) | 19.2 | 17.5 | 0.74 |
Dofetilide (%) | 1.5 | 0.9 | 1.00 |
Sotalol (%) | 3.1 | 3.5 | 1.00 |
Class I Antiarrhythmics (%) | 3.1 | 5.3 | 0.52 |
NOAC (%) | 20.0 | 17.5 | 0.63 |
Warfarin(%) | 34.6 | 16.7 | 0.001 |